Background & Aims
There is an urgent demand for non-addictive analgesics with enhanced safety in clinical post-surgical pain management, to prevent the side effects, addiction and abuse of opioids. Although a few long-acting sustained-release formulations containing Bupivacaine (Bu) have been approved (Exparel® and its generic drug Aihengping(AHP, CHN brand ???®)) or in research (Probudur), their analgesic duration is notably behind the time of 30 days expected by FDA. Additionally, safety concerns remain regarding cardiovascular (CV) and central nervous system (CNS) toxicity caused by high content of Bu in these formulations. It has been reported that Exparel has a significant correlation with systemic toxicity (LAST, including CV and CNS toxicity), specifically a mortality as high as 8.5% among 130 reported toxic cases. To obtain new ultra-long-acting safe analgesic, we modified the structure of amide local anesthetics and developed a new serial of tert-amine analgesic molecules, among which is EL012.
Methods
EL012 hydrochloride and positive controls (Bu, Levobupivacaine(LBu)) were dissolved in normal saline to prepare different concentrations of solutions, and their analgesic effects were evaluated in Hartley guinea pigs and SD rats, by defining the inhibition of the cutaneous trunci muscle reflex in pin-prick (PP) tests after subcutaneous (SC) injections of 0.6 ml solutions. Similar PP test in rats by 26g von Frey filament was also carried out for EL012 and AHP. At various time after injection in rats, the concentration at the injection site (SC), the systemic residue and elimination (SC), as well as the drug distribution in the brain after intravenous injection (IV) were measured for EL012 and Bu. In vitro, the efficacy and the cardiotoxity of EL012 were compared with Bu through the IC50 values of human Nav1.7 and Nav1.5. The safety of EL012 was further investigated using LD50 in mice, local histopathology at injection site and wound healing test in rats.
Results
1) 50% efficient analgesic duration (PP test, SC): a) Guinea pigs (10.0mM): 96h (n=9) for EL012 and 2h (n=10) for Bu; b) Rats (10.0 mM): 192h (n=8) for EL012 and 4h (n=3) for LBu; c) Rats (by 26g von Frey filament): 96h (n=10) for EL012 (2.8mM) and 3h (n=10) for AHP (46.1mM), and the efficiency-time AUC of EL012 is about 280% of AHP (0.083-264h). 2) IC50 of Nav1.5 and Nav1.7: 21.08 and 16.70 ?M for EL012; 6.84 and 20.73 ?M for Bu. 3) Max-concentration in brain (10min, rats, IV): 0.089 nmol/g for EL012 and 4.417 nmol/g for Bu. 4) Local concentration (rats, SC, 10mM): 1220.8-462.3µg/g for EL012 (0.42-5h) and 717.3-4.8µg/g for Bu (0.33-5h), respectively. 5) Elimination (240h, rats, SC, 3.5mM): 3.2nmol/g at injection site, and below the limit of detection in blood or organ tissue. 6) Histological examination (312h, rats, SC, 2.8mM): minimal to no irritant response observed. 7) LD50 (mice, IV): 17.5 mg/kg for EL012 and 6.78 mg/kg for Bu. 8) Wound healing (rats): no significant difference among EL012 (7.7mM), Bu (7.7mM), and saline groups.
Conclusions
Our studies show that the newly designed EL012 has a much longer local retention time, and long-acting analgesic duration to be 48 times longer than Bu and LBu after SC administration in guinea pigs and rats. The same locally administered EL012 has a 32 times longer analgesic duration than AHP, a long-acting sustained-release formulation of Bu liposomes, even though the dosage of EL012 is less than 1/16 of the Bu contained in AHP. In addition, EL012 has a potentially lower CV and CNS toxicity than Bu, as well as potentially higher general safety, based on lower concentration in brain (2% of Bu), higher IC50 value of Nav1.5 (3 times higher than Bu), rare irritation by pathological examination, and greater mice LD50 value of EL-012 in vivo assays. Therefore, EL012, a tert-amine analgesic molecule, is very promising to be developed into a novel non-opioid analgesic drug that can be administered locally, characterized by ultra-long-acting analgesic effects and enhanced safety.
References
Opioid crisis and side effects:
[1]Volkow N.D., Blanco C. The changing opioid crisis: Development, challenges and opportunities. Mol. Psychiatry. 2021;26:218–233.
[2]Gregorian RS, Gasik A, Kwong WJ, et al.. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain 2010;11:1095–108.
Exparel information:
[3]FDA Exparel Label.
[4]FDA Exparel Pharmacology Review.
Aihengping information:
[5]Aihengping information on website of National Healthcare Security Administration https://www.nhsa.gov.cn/attach/Ypsn2023/YPSW202300088/YPSW202300088-W1(ppt).pdf
Probudur information:
[6]https://virpaxpharma.com/products/#Product-Pipeline
[7]Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research. https://virpaxpharma.com/2023/10/12/virpax-pharmaceuticals-announces-extension-of-crada-with-the-u-s-army-institute-of-surgical-research/
FDA guidance for non-opiod anagesics development:
[8]GUIDANCE DOCUMENT. Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-acute-pain-draft-guidance-industry
Controversial views on Exparel’s efficacy:
[9]Fidkowski CW, Choksi N, Alsaden MR. A randomized-controlled trial comparing liposomal bupivacaine, plain bupivacaine, and the mixture of liposomal bupivacaine and plain bupivacaine in transversus abdominus plane block for postoperative analgesia for open abdominal hysterectomies. Can J Anesth, 2021, 68(6):773-781.
[10]Hattrup SJ, Chung AS, Rosenfeld DM, etal. Liposomal bupivacaine interscalene nerve block in shoulder arthroplasty is not superior to plain bupivacaine : a double blinded prospective randomized control trial. J Shoulder Elb Surg, 2021, 30(3):587-598.
[11]Yeap YL, Wolfe J, Stewart J, et al. Liposomal bupivacaine addition versus standard bupivacaine alone for colorectal surgery: a randomized controlled trial. Pain Manag, 2022, 12(1): 35-43.
[12]Hungerford M, Neubauer P, Ciotola J, etal. Liposomal bupivacaine vs ropivacaine for adductor canal blocks in total knee arthroplasty: a prospective randomized trial. J Arthroplasty, 2021,36(12):3915-3921.
[13]Ilfeld BM, Eisenach JC, Gabriel RA. Clinical effectiveness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain. Anesthesiology, 2020,134(2):283-344.
[14]Ji YD, Harris JA, Gibson LE, etal. The efficacy of liposomal bupivacaine for opioid and pain reduction: a systematic review of randomized clinical trials. J Surg Res, 2021, 264(8):510-533.
CV and CNS toxicity of bupivacaine and liposomal bupivacaine:
[15]Marc E Levsky, Michael A Miller. Cardiovascular collapse from low dose bupivacaine. Can J Clin Pharmacol. 2005 Fall;12(3):e240-5. Epub 2005 Oct 24.
[16]John F Butterworth 4th. Models and mechanisms of local anesthetic cardiac toxicity: a review. Reg Anesth Pain Med. 2010 Mar-Apr;35(2):167-76.
[17]K Knudsen, M Beckman Suurküla, S Blomberg, J Sjövall, N Edvardsson. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth. 1997 May;78(5):507-14.
[18]Ho Yoel Ryu , Jang-Young Kim, Hyun Kyo Lim, Junghan Yoon, Byung-Su Yoo, Kyung-Hoon Choe, Seung-Hwan Lee. Bupivacaine induced cardiac toxicity mimicking an acute non-ST segment elevation myocardial infarction. Yonsei Med J. 2007 Apr 30;48(2):331-6.
[19]WALDINGER R, WEINBERG G, GITMAN M. Local anesthetic toxicity in the geriatric population. Drugs Aging, 2020, 37(1): 1-9.
[20]Ajay Mahajan, Armen Derian. Local Anesthetic Toxicity. Book. StatPearls Publishing; 2024 Jan.
[21]Nitish Aggarwal. Local anesthetics systemic toxicity association with exparel (bupivacaine liposome)- a pharmacovigilance evaluation. Expert Opin Drug Saf. 2018 Jun;17(6):581-587.
[22]Michael O On’Gele, Sara Weintraub, Victor Qi , James Kim. Local Anesthetics, Local Anesthetic Systemic Toxicity (LAST), and Liposomal Bupivacaine. Anesthesiol Clin. 2024 Jun;42(2):303-315.
[23]N Shibuya, N Hatakeyama, M Yamazaki, A Masuda, Y Ito, Y Momose Masui. Inhibitory action of bupivacaine on cardiac contraction. The Japanese Journal of Anesthesiology 1993 Sep;42(9):1306-12.
EL012 patent information:
[24]N-substituted Arylamine Derivative, and Preparation Method Therefor and Use Thereof. Publication Number: WO/2024/012397
Pin-prick test method:
[25]Mohammed A. Khan, M.D.,* Peter Gerner, M.D.,† Ging Kuo Wang, Ph.D.‡ Amitriptyline for Prolonged Cutaneous Analgesia in the Rat, Anesthesiology 2002; 96:109–16.
Pharmacokinetics of bupivacaine:
[26]Yuko Ikeda, Yutaka Oda, Taketo Nakamura, Ryota Takahashi, Wakako Miyake, Ichiro Hase, Akira Asada. Pharmacokinetics of lidocaine, bupivacaine, and levobupivacaine in plasma and brain in awake rats. Anesthesiology. 2010 Jun;112(6):1396-403.
Bupivacaine’s effect on cardiac sodium channels:
[27]Alexander P Schwoerer, Hanno Scheel, Patrick Friederich. A Comparative Analysis of Bupivacaine and Ropivacaine Effects on Human Cardiac SCN5A Channels. Anesth Analg. 2015 Jun;120(6):1226-34.
[28]Heng Zhang, Hui Ji, Zhirui Liu, Yonghua Ji, Xinmin You, Gang Ding, Zhijun Cheng. Voltage-dependent blockade by bupivacaine of cardiac sodium channels expressed in Xenopus oocytes. Neurosci Bull. 2014 Aug;30(4):697-710.
Presenting Author
Qingeng Li
Poster Authors
Qingeng Li
Professor
Jiangsu Nhwa-Luokang Pharmaceutical R&D Co., Ltd.
Lead Author
Jie Chen
Lead Author
Changwen Li
Lead Author
Kai Wang
Lead Author
Yi Shen
Lead Author
Xiaohu Dong
Lead Author
Shuai Jiang
Lead Author
Qianling Yang
Lead Author
Yan Liu
Lead Author
Jingyuan Wan
Lead Author
Qingsong Jiang
Lead Author
Wengao Jiang
Lead Author
Topics
- Specific Pain Conditions/Pain in Specific Populations: Post-surgical/Post-traumatic Chronic Pain